Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetic issues in thorough QT trials.

Richard S Judson1, Benjamin A Salisbury, Carol R Reed

  • 1SpyroPharma, Guilford, Connecticut, USA.

Molecular Diagnosis & Therapy
|June 15, 2006
PubMed
Summary

Drug-induced QT prolongation (DI-LQT) poses a significant risk, leading to drug withdrawals. This review explores how genetic variants influence DI-LQT risk and suggests using pharmacogenetics in Thorough QT (TQT) study design.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigation of the Impact of Wellinks on the Quality of Life and Clinical Outcomes in Patients With Chronic Obstructive Pulmonary Disease: Interventional Research Study.

JMIR formative research·2024
Same author

Computational pharmacogenotype extraction from clinical next-generation sequencing.

Frontiers in oncology·2023
Same author

Retention, Fasting Patterns, and Weight Loss With an Intermittent Fasting App: Large-Scale, 52-Week Observational Study.

JMIR mHealth and uHealth·2022
Same author

Analytical Validation of a Computational Method for Pharmacogenetic Genotyping from Clinical Whole Exome Sequencing.

The Journal of molecular diagnostics : JMD·2022
Same author

An Integrated, Multimodal, Digital Health Solution for Chronic Obstructive Pulmonary Disease: Prospective Observational Pilot Study.

JMIR formative research·2022
Same author

Strongest Evidence Revisited.

Cladistics : the international journal of the Willi Hennig Society·2021

Area of Science:

  • Pharmacology
  • Genetics
  • Cardiology

Background:

  • Drug-induced QT prolongation (DI-LQT) is a major reason for drug market withdrawal.
  • Regulatory agencies mandate Thorough QT (TQT) studies to assess QT liability for new drugs.
  • Genetic factors, including congenital long QT syndrome genes and drug metabolism genes (CYP2D6, CYP3A4), influence DI-LQT risk.

Purpose of the Study:

  • To review the relationship between genetic variants and drug-induced QT risk.
  • To propose methods for incorporating pharmacogenetics into TQT study planning and analysis.

Main Methods:

  • Literature review of genetic factors associated with DI-LQT.
  • Analysis of existing TQT study designs and pharmacogenetic data.

Related Experiment Videos

Main Results:

  • Identified key genetic variants impacting QT interval and arrhythmia risk.
  • Highlighted the role of CYP2D6 and CYP3A4 in drug metabolism and QT prolongation.
  • Demonstrated potential for pharmacogenetics to refine TQT study approaches.

Conclusions:

  • Genetic variations significantly modulate an individual's susceptibility to DI-LQT.
  • Pharmacogenetic insights can enhance the precision and efficiency of TQT studies.
  • Integrating pharmacogenetics may improve drug safety assessments and reduce unnecessary withdrawals.